Most used for Most used for Fat Loss.
AOD 9604 is a synthetic peptide derived from the C-terminal region of human growth hormone consisting of 15 amino acids. It was developed to replicate the fat-reducing effects of growth hormone without affecting overall growth or insulin-like growth factor activity. Studies in animals and humans suggest it promotes fat breakdown and inhibits fat formation through metabolic regulation.
Research use only (not for human use)
Performance-enhancing / prohibited
AOD 9604 is a synthetic peptide fragment derived from human growth hormone. It consists of the last 15 amino acids of the growth hormone’s 191-amino-acid chain, modified to enhance specific metabolic effects.
It is purported to aid in fat metabolism by stimulating the breakdown of stored fat and inhibiting the formation of new fat. Some claim it can support weight management and improve recovery by promoting more efficient energy use in the body.
AOD 9604 primarily benefits fat metabolism by promoting lipolysis, the breakdown of fat, and inhibiting lipogenesis, the creation of new fat, which supports fat loss especially when combined with diet and exercise. Studies show that it mimics the fat-reducing effects of human growth hormone without significantly affecting IGF-1 levels or carbohydrate metabolism, allowing it to aid in fat reduction without altering broader endocrine functions. Animal studies indicate that AOD 9604 may also limit the formation of new fat cells, which could support long-term weight maintenance 1.
Additionally, AOD 9604 has shown potential to support tissue regeneration, including promoting differentiation processes important for bone, cartilage, and muscle repair. Research in vitro and animal models suggests it may enhance the synthesis of proteins vital for tissue integrity and repair 2. There is also exploratory evidence from cancer research indicating AOD 9604 could enhance the effectiveness of chemotherapeutic agents in breast cancer cells, possibly by facilitating drug binding to target proteins 3. Overall, AOD 9604 demonstrates potential as a multifaceted peptide that not only aids in fat reduction but may also contribute to tissue repair and enhance therapeutic outcomes in certain cellular contexts.
Clinical trials of AOD 9604 have generally reported a good safety profile with few consistent negative side-effects in humans. In six randomized, double-blind, placebo-controlled trials involving around 890 subjects, AOD 9604 showed no increases in insulin-like growth factor-1 (IGF-1), no impairment of glucose tolerance, and no anti-AOD 9604 antibodies detected. Adverse events in the intravenous dose-escalation study included headache, fatigue, dizziness, nasopharyngitis, cough, abdominal pain, injection site bruising and pain, but none were severe or clearly linked to the study drug 4.
In animal studies the side-effect burden also appears modest. Rodent studies showed that while AOD 9604 induced fat loss and increased lipolysis, it did not lead to insulin resistance (unlike full length growth hormone) 5. There remain some reports in non-peer-review sources (not formally in the clinical trial data) suggesting possible injection-site reactions such as redness, itching or swelling, headaches, chest tightness, palpitations or mild euphoria. Because the long-term safety data are limited, especially for off-label routes or doses, these potential side-effects should be considered in context of the limited evidence base.
AOD 9604 is a short peptide derived from the C-terminal region of human growth hormone that was designed to retain GH’s fat-mobilizing effects. Studies in rodents and mice show that it increases lipolysis, raises fat oxidation, and reduces fat mass without activating the full GH–IGF-1 axis. Research using β3-adrenergic receptor knockout mice and related experiments indicates that AOD 9604’s lipolytic actions depend on β3-adrenergic signaling and on increasing adipose β3-AR expression rather than on high-affinity GH receptor binding. These findings come from metabolic and chronic-treatment studies in animals and from early human metabolism and safety reports 6.
The FDA has not approved AOD-9604 for any human therapeutic use and specifically lists AOD-9604 among “certain bulk drug substances” that may present significant safety risks and for which the agency lacks sufficient safety information for human administration (i.e., compounding with AOD-9604 is not supported) 7. In sport, WADA classifies growth-hormone fragments (explicitly including AOD-9604) under the prohibited list (S2, peptide hormones and related substances). WADA and related anti-doping guidance treat AOD-9604 as a banned substance for competitive sport 8.
